PressDecember 9, 2024 MindBio Announces Completion of Private Placement and Issuance of Listed Securities
PressDecember 9, 2024 Bionomics Publishes the Positive Results from the Phase 2 ATTUNE Study of BNC210 in Patients with Post-Traumatic Stress Disorder in NEJM Evidence
PressDecember 6, 2024 Psyence Group Enters Into Agreements With Its NASDAQ-Listed Associate, Psyence Biomedical, To Settle Outstanding Obligations
PressDecember 6, 2024 MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)
PressDecember 6, 2024 MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy
PressDecember 2, 2024 Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management
PressNovember 25, 2024 Revitalist Releases Benefits Program Giving Access To All for Ketamine Therapies Changing the Narrative of Mental Health to Risk Mitigation
PressNovember 20, 2024 Psyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications Hearing
PressNovember 19, 2024 Lobe Sciences and Alera Pharma Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™
PressNovember 18, 2024 MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer
PressNovember 18, 2024 Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
PressNovember 18, 2024 Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders
PressNovember 15, 2024 Numinus Wellness Announces Sale of Clinics and Unique Data Partnership to Increase Access to Mental Health Care
PressNovember 15, 2024 Filament Health Announces Third Quarter 2024 Financial Results and Operational Highlights
PressNovember 14, 2024 Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
PressNovember 14, 2024 PharmAla Reaches Agreement in Principle to Supply MDMA to Clinical Trial in Exchange for Full Data License
PressNovember 13, 2024 Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq Form 6 K
PressNovember 13, 2024 Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results
